MOUNTAIN VIEW, Calif., Feb. 21 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, announced today that Bill Poland, Ph.D., Senior Scientist, will speak to members of the pharmaceutical and biotechnology industries via web conference on HIV drug-disease modeling on February 28, 2006 at 1:30 PM Eastern Time.
Dr. Poland's presentation, titled "Modeling and Simulation to Support HIV Drug Development Decisions" will discuss the use and strategic value of integrated adherence, PK-PD, and trial modeling and simulation for antiretrovirals approaching Phase II/III development. More information is available at http://www.pharsight.com/events/events_home.php .
"HIV presents special therapeutic challenges to the drug development team, including resistance, complex pharmacokinetics, and patient compliance," said Shawn O'Connor, President and CEO of Pharsight. "Our modeling and simulation approach in HIV, as in other therapeutic domains, is to integrate relevant sub-models, estimate key parameters from trial data, and simulate candidate trial designs. The business benefits can include optimizing the design of the next trial or sequence of trials, better go/no-go decisions, and strategies to optimize unavoidable tradeoffs such as that between patient compliance and difficult dosing."
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com .
Forward Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding anticipated performance of Pharsight's services and the expected benefits to customers from the use of such services. Actual results may differ materially from Pharsight's expectations due to a variety of factors, including general market and business conditions, uncertainties involved in pharmaceutical drug development, changes in the demand for Pharsight's services, the failure to develop new services or to keep pace with technological changes, the failure of Pharsight's services to obtain anticipated levels of customer acceptance or to meet customers' expectations, and changes in government regulation of the pharmaceutical industry. Further information on potential factors that could affect actual results is included in Pharsight's Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on February 13, 2006. All forward-looking statements are based on information available to Pharsight as of the date hereof, and Pharsight assumes no obligation to update such statements, whether as a result of new developments or otherwise.
NOTE: Registered Trademarks and Trademarks
Pharsight(R) is a registered trademark of Pharsight Corporation.
Pharsight CorporationCONTACT: investors, Douglas Sherk, +1-415-896-6820, or JenniferBeugelmans, +1-415-896-6820, or Media, Steve DiMattia, +1-646-277-8706, allof EVC Group, for Pharsight
Web site: http://www.pharsight.com/
